Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 494 entries
View as:

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Phase: N/A Priority: Normal
NCT ID: NCT04571424 Org: User:
Start: 10/14/20 End: 04/08/21 Due: 04/08/22

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Phase: N/A Priority: Normal
NCT ID: NCT00574041 Org: User:
Start: 06/30/07 End: 02/29/08 Due: 02/28/09

Plegridy Observational Program

Phase: N/A Priority: Normal
NCT ID: NCT02230969 Org: User:
Start: 11/12/14 End: 01/20/22 Due: 01/20/23

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Phase: N/A Priority: Normal
NCT ID: NCT04442503 Org: User:
Start: 06/08/20 End: 04/12/22 Due: 04/12/23

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01500408 Org: User:
Start: 01/31/12 End: 04/30/12 Due: 04/30/13

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01503866 Org: User:
Start: 12/01/11 End: 12/31/11 Due: 12/31/12

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Phase: N/A Priority: Normal
NCT ID: NCT01873417 Org: User:
Start: 05/31/13 End: 11/30/13 Due: 11/30/14

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT01576887 Org: User:
Start: 07/31/12 End: 10/31/12 Due: 10/31/13

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Phase: N/A Priority: Normal
NCT ID: NCT06623890 Org: User:
Start: 12/12/24 End: 10/01/29 Due: 10/01/30

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01416207 Org: User:
Start: 08/31/11 End: 10/31/11 Due: 10/31/12

Study of Diroximel Fumarate in the Real-World Setting

Phase: N/A Priority: Normal
NCT ID: NCT04746976 Org: User:
Start: 03/01/21 End: 04/14/23 Due: 04/14/24

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00103558 Org: User:
Start: 03/31/04 End: 03/31/10 Due: 03/31/11

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

Phase: N/A Priority: Normal
NCT ID: NCT01070836 Org: User:
Start: 03/31/10 End: 11/30/15 Due: 11/30/16

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01397539 Org: User:
Start: 06/30/11 End: 08/31/13 Due: 08/31/14

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00345189 Org: User:
Start: 02/28/06 End: 04/30/09 Due: 04/30/10

Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate

Phase: N/A Priority: Normal
NCT ID: NCT02090348 Org: User:
Start: 06/30/15 End: 10/31/17 Due: 10/31/18

Tecfidera and the Gut Microbiota

Phase: N/A Priority: Normal
NCT ID: NCT02471560 Org: User:
Start: 11/06/15 End: 06/12/17 Due: 06/12/18

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a

Phase: N/A Priority: Normal
NCT ID: NCT00771043 Org: User:
Start: 11/01/08 End: 06/01/10 Due: 06/01/11

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

Phase: N/A Priority: Normal
NCT ID: NCT01632449 Org: User:
Start: 07/31/12 End: 09/30/12 Due: 09/30/13

BG00012 Regional Absorption Study

Phase: N/A Priority: Normal
NCT ID: NCT01924832 Org: User:
Start: 08/31/13 End: 04/30/14 Due: 04/30/15

Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00105170 Org: User:
Start: 01/31/05 End: 08/31/06 Due: 08/31/07

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT05655507 Org: User:
Start: 04/19/23 End: 10/18/24 Due: 10/18/25

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Phase: N/A Priority: Normal
NCT ID: NCT01939002 Org: User:
Start: 11/30/13 End: 11/30/15 Due: 11/30/16

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT03222973 Org: User:
Start: 11/15/17 End: 02/12/21 Due: 02/12/22

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00390221 Org: User:
Start: 02/29/08 End: 08/31/11 Due: 08/31/12